Publications by authors named "Roberta Caputo"

Claim this Profile
I
In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer.
Michelino De Laurentiis, Roberto Buonaiuto, Giuseppe Buono, Roberta Caputo, Carmine De Angelis

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.
Roberto Buonaiuto, Mario Fordellone, Aldo Caltavituro, Maria Letizia Cataldo, Carmen Criscitiello, Roberta Caputo

EClinicalMedicine· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
Roberta Scafetta, Marco Donato, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Roberta Caputo

Breast· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER).
Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi, Mauro Mansutti, Zelmira Ballatore, Roberta Caputo

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic implications of risk definitions from the monarchE and NATALEE trials.
Luca Arecco, Eva Blondeaux, Marco Bruzzone, Grazia Arpino, Carmine De Angelis, Roberta Caputo

J Natl Cancer Inst· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.
Pietro De Placido, Rossana Di Rienzo, Erica Pietroluongo, Claudia Martinelli, Margherita Tafuro, Roberta Caputo

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regions.
Raffaele Ardito, Grazia Arpino, Roberta Caputo, Mariangela Ciccarese, Sabino De Placido

Sci Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis.
Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Roberta Caputo

Breast· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T cell therapy for breast cancer: Current status and future perspective.
Giuseppe Buono, Monica Capozzi, Roberta Caputo, Vincenzo Di Lauro, Daniela Cianniello

Cancer Treat Rev· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.
Pier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, Fabiola Giudici, Antonio Marra, Roberta Caputo

JAMA Netw Open· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.
Alessandra Fabi, Alessandro Rossi, Roberta Caputo, Simona Pisegna, Simone Scagnoli

NPJ Precis Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis

NPJ Breast Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis

NPJ Breast Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients.
Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, Roberta Caputo, Monica Marino

Breast· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Andrea Botticelli, Roberta Caputo, Simone Scagnoli, Simona Pisegna, Michelino De Laurentiis

Oncologist· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
Eva Blondeaux, Wanling Xie, Luca Carmisciano, Silvia Mura, Valeria Sanna, Roberta Caputo

EClinicalMedicine· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
Roberta Caputo, Giuseppe Buono, Michela Piezzo, Claudia Martinelli, Daniela Cianniello

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients.
Anna Crispo, Livia S A Augustin, Assunta Luongo, Claudia Calderaio, Joao Breda, Roberta Caputo

Sci Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.
Andrea D'Arienzo, Annarita Verrazzo, Martina Pagliuca, Fabiana Napolitano, Sara Parola, Roberta Caputo

EClinicalMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.
Roberta Caputo, Martina Pagliuca, Matilde Pensabene, Sara Parola, Michelino De Laurentiis

Front Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Roberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, Daniela Cianniello, Claudia Von Arx

Future Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi

Eur J Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
Matteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, Silvia Mura, Sabino De Placido, Roberta Caputo

EClinicalMedicine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Michelino De Laurentiis, Roberta Caputo, Manuelita Mazza, Mauro Mansutti, Riccardo Masetti

Target Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial.
Roberta Caputo, Alessandra Fabi, Emanuela Romagnoli, Editta Baldini, Donatella Grasso

Breast Cancer (Dove Med Press)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis